Location History:
- Union, NJ (US) (2012)
- Summit, NJ (US) (2000 - 2022)
Company Filing History:
Years Active: 2000-2022
Title: The Innovative Contributions of Ingrid Birgitta Carlbom
Introduction
Ingrid Birgitta Carlbom, an accomplished inventor based in Summit, NJ, has made significant advancements in the field of pathology through her innovative methods in histological tissue image analysis. With a remarkable portfolio of 19 patents, Carlbom has established herself as a leading figure in the intersection of medical technology and artificial intelligence.
Latest Patents
Two of Carlbom's latest patents showcase her expertise in prostate cancer classification. The first patent, titled "Segmentation of histological tissue images into glandular structures for prostate cancer tissue classification," presents a novel method that employs color decomposition to create a density map. This map identifies stroma and glandular structures within tissue images, enhancing the identification process for glandular regions. The refined technique involves adaptive morphological operations to optimize gland extractions and classification based on associated features.
Her second patented innovation, "Prostate cancer tissue image classification with deep learning," focuses on utilizing a trained deep learning network to classify nuclei within prostate tissue images. This approach not only segments the glands but also evaluates the malignancy grade of the surrounding tissue, streamlining the diagnostic process through automation and expert categorization.
Career Highlights
Ingrid Carlbom's professional journey has led her to work with prominent companies such as Lucent Technologies Inc. and Agere Systems Inc., where she honed her skills and contributed to pivotal research initiatives. Her dedication to advancing medical imaging technologies has paved the way for enhanced accuracy in cancer diagnostics.
Collaborations
Throughout her career, Carlbom has collaborated with notable colleagues, including Yves Darly Jean and Thomas A. Funkhouser. These partnerships have fostered a collaborative environment, driving innovative solutions in the realm of medical technology and promoting the development of intelligent systems for diagnostic purposes.
Conclusion
Ingrid Birgitta Carlbom's contributions to pathology and cancer research exemplify the crucial role of innovation in medical technology. With her extensive patent portfolio and collaborative efforts, Carlbom continues to lead the charge in transforming the way prostate cancer is diagnosed and understood. Her work not only advances the field but also provides hope for improved outcomes in patient care.